-
Revenue in Q3 2026 increased 39% to$24.4 billiondriven primarily by Mounjaro and Zepbound.
-
Q3 revenue included approximately$900 millionof benefits, primarily from$410 millionof Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.
-
Q3 2026 EPS increased by 16% to$7.22on a reported basis and increased by 7% to$7.48on a non-GAAP basis. Q3 2026 reported and non-GAAP EPS included$4.57of acquired IPR&D charges compared to$0.71in Q3 2025.
-
Increased the midpoint of our 2026 full-year revenue guidance by$5.5 billionto be in the range of$91.0to$92.0 billionand raised underlying non-GAAP EPS guidance for the full year by$4.07at the midpoint, which was more than offset by$4.57of acquired IPR&D charges from Q3 business development activity, resulting in an updated range of$35.00to$36.00.
-
Regulatory progress includedU.S.FDAapprovals of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes; Onswik, a once-weekly basal insulin for adults with type 2 diabetes; Inluriyo with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer; and an expanded indication for Jaypirca in adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
Pipeline highlights included positive topline results from a head-to-head Phase 3 trial of retatrutide versus Ozempic 2 mg in adults with type 2 diabetes, Phase 3 results from Ebglyss in moderate-to-severe hand and foot atopic dermatitis and Phase 2 results from EloraTZP in adults with obesity and type 2 diabetes, with Phase 3 trials to start in Q4 2026.
-
Business development activity in Q3 2026 included the completed acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. Subsequent to quarter end, we completed the acquisition of Merida Biosciences, to advance treatments for serious autoimmune and allergic diseases.
INDIANAPOLIS, Oct. 29, 2026 /PRNewswire/ --Eli Lilly and Company(NYSE: LLY) today announced its financial results for the third quarter of 2026 and provided updated 2026 financial guidance.
"Lillyhad another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook," saidDavid A. Ricks,Lillychair and CEO. "Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expandedU.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions inTexasandVirginia.Lillyis executing well across the value chain, and our potential for impact on human health continues to expand."
Financial Results
A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)."
Third-Quarter Reported Results
In Q3 2026, worldwide revenue was$24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume, partially offset by a 15% decrease in realized prices. Key Products1 revenue grew to$17.1 billionin Q3 2026, led by Mounjaro and Zepbound. Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 100% in Q3 2026 compared to Q3 2025.
Revenue in theU.S. increased 34% to$15.1 billion, driven by a 41% increase in volume, partially offset by a 7% decrease in realized prices. The increase inU.S. volume was driven by Zepbound and Mounjaro. The decline in realized prices was primarily driven by Zepbound, partially offset by adjustments to estimates for rebates and discounts.
Revenue outside theU.S. increased 47% to$9.3 billion, driven by a 76% increase in volume, partially offset by a 29% decrease in realized prices. The volume increase outside theU.S. was driven by Mounjaro. Jardiance revenue outside theU.S. included sales-based milestones of$410 millionin Q3 2026 and$200 millionin Q3 2025, associated with the company's collaboration withBoehringer Ingelheim. Additionally, Q3 2025 revenue included$180 millionassociated with the divestiture of the rights to Cialis in select markets outside of theU.S. Lower realized prices outside theU.S. were driven primarily by the inclusion of Mounjaro on the National Reimbursement Drug List (NRDL) inChina.
Gross margin increased 40% to$20.5 billionin Q3 2026. Gross margin as a percent of revenue was 83.9%, an increase of 1.0 percentage points versus the same quarter last year. The increase was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices.
In Q3 2026, research and development expenses increased 23% to$4.2 billion, or 17% of revenue, driven by continued investments in the company's early and late-stage portfolio.
Marketing, selling, and administrative expenses increased 14% to$3.1 billionin Q3 2026, primarily driven by promotional efforts supporting ongoing and planned launches.
In Q3 2026, the company recognized acquired in-process research and development (IPR&D) charges of $4.2 billion compared with$656 millionin Q3 2025. The Q3 2026 charges primarily related to the acquisitions ofAtaiBeckley Inc.andCurevo Inc.
The effective tax rate was 23.3% in Q3 2026 compared with 22.8% in Q3 2025, primarily driven by the unfavorable tax impact of nondeductible acquired IPR&D charges, with a larger impact occurring in 2026. The Q3 2025 effective tax rate was also unfavorably impacted byU.S. tax law changes.
In Q3 2026, net income and earnings per share (EPS) were$6.5 billion and$7.22, respectively, compared with net income of$5.6 billion and EPS of$6.21in Q3 2025. EPS in Q3 2026 and Q3 2025 included acquired IPR&D charges of$4.57and$0.71, respectively.
1 The Company currently defines Key Products as Ebglyss, Foundayo, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound.
Third-Quarter Non-GAAP Measures
On a non-GAAP basis, Q3 2026 gross margin increased 40% to$20.6 billion. Gross margin as a percent of revenue was 84.4%, an increase of 0.8 percentage points versus the same quarter last year. The increase was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices.
The non-GAAP effective tax rate was 24.0% in Q3 2026 compared with 17.7% in Q3 2025, primarily driven by the unfavorable tax impact of nondeductible acquired IPR&D charges, with a larger impact occurring in 2026.
On a non-GAAP basis, Q3 2026 net income and EPS were$6.7 billionand$7.48, respectively, compared with net income of$6.3 billion and EPS of$7.02in Q3 2025. Non-GAAP EPS in Q3 2026 and Q3 2025 included acquired IPR&D charges of$4.57and$0.71, respectively.
For further detail on non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)" table later in this press release.
2026 Financial Guidance
In addition to providing guidance for GAAP revenue,Lillyprovides guidance for certain non-GAAP measures.
The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflecting strong underlying performance across our portfolio. The first three quarters of 2026 also benefited from sales-based milestones and adjustments to estimates for rebates and discounts.
In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of$4.07(at the midpoint of the range), offset by$4.57associated with the Q3 acquired IPR&D charges from recent business development activity:
Non-GAAP Financial Measures
Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance withU.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Historical non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates.Lillyrecalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2026 financial guidance (other than revenue) is provided on a non-GAAP basis, as described in "2026 Financial Guidance" above. Non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.
About Lilly
Lillyis a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.